Every Form 4 that Cogent Biosciences, Inc. (COGT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow COGT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COGT filings page.
Cogent Biosciences, Inc. director Karen Jean Ferrante received a direct award of options covering 759 shares of common stock on October 1, 2026. The options have an exercise price of $31.59 per share and expire October 1, 2036. The award followed her election to take shares in lieu of cash compensation for director services; the option count was based on the quarter’s cash compensation otherwise payable divided by the Black-Scholes value of one option calculated on the grant date.
Cogent Biosciences, Inc. (COGT) director Arlene Morris reported option exercises and related share sales in Cogent Biosciences stock. On 2026-08-27 she exercised stock options for 45,510 shares of common stock (41,927 at an exercise price of $5.64 per share and 3,583 at $2.52 per share), from fully vested awards. The same day she sold 45,510 shares of common stock in open-market transactions at weighted average prices of $37.0925 and $37.5396 per share, with actual sale prices ranging from $36.46–$37.65 per share. All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 28, 2026.
Cogent Biosciences director Karen Jean Ferrante reported receiving a grant of stock options as compensation. On July 1, 2026, she was awarded 627 stock options to buy Cogent Biosciences common stock at an exercise price of $38.48 per share.
The options were issued under the company’s non-employee director compensation plan after she elected to take equity instead of cash fees for the quarter. These options expire on July 1, 2036, and following the grant she holds 627 derivative securities directly.
Cogent Biosciences, Inc. reported that director Peter Evan Harwin was granted a stock option covering 17,901 shares of common stock at an exercise price of $31.98 per share. The option expires on June 9, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, subject to his continued service. According to the disclosed arrangement, the option is held for investment vehicles managed by Fairmount Funds Management LLC, and Harwin is required to turn over any net cash or stock to the adviser, so he disclaims beneficial ownership.
Cogent Biosciences, Inc. director Karen Jean Ferrante received a new stock option grant covering 17,901 shares of common stock. The option has an exercise price of $31.98 per share and expires on June 9, 2036.
According to the award terms, the option will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, provided she continues serving the company through that date. Following this grant, she holds 17,901 stock options directly.
Cogent Biosciences, Inc. director Christopher W. Cain is associated with a grant of stock options covering 17,901 shares of common stock at an exercise price of $31.98 per share. The option expires on June 9, 2036 and vests in full upon the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, subject to continued service.
Under an arrangement with Fairmount Funds Management LLC, Cain holds this option for one or more Fairmount investment funds and must turn over any net cash or stock received for the benefit of those funds. He therefore disclaims beneficial ownership of the option and the underlying common stock.
Cogent Biosciences director Todd Shegog received a new stock option award covering 17,901 shares of common stock. The options have an exercise price of $31.98 per share and expire on June 9, 2036. This grant increases his direct derivative holdings to 17,901 option shares.
The option will vest in full on the earlier of the first anniversary of the grant date or the date of the company’s 2027 Annual Meeting of Stockholders, provided Shegog continues to serve the company through that date. Until vesting and exercise, the award represents potential, not current, share ownership.
Cogent Biosciences director Arlene Morris received a stock option grant for 17,901 shares of common stock. The options have an exercise price of $31.98 per share and expire on June 9, 2036, representing compensation rather than an open-market trade.
The option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the 2027 Annual Meeting of Stockholders, provided she continues serving the company through that date. After this grant, she directly holds stock options covering 17,901 underlying shares.
Cogent Biosciences director Matthew Ros received a stock option grant, not an open‑market trade. He was awarded options for 17,901 shares of common stock at an exercise price of $31.98 per share, expiring on June 9, 2036. The option vests in full on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of Stockholders, conditioned on his continued service to the company through that date.
Cogent Biosciences President and CEO Andrew Robbins reported two bona fide gifts of common stock. On May 19, 2026, he transferred 160,000 shares to a family trust for estate planning purposes and made a separate 160,000-share gift from his direct holdings.
After these transfers, Robbins’ direct ownership stands at 497,503 common shares, and the family trust holds 160,000 shares as an indirect position. These transactions were recorded at a price of $0.00 per share, reflecting that they were gifts rather than market sales.
Cogent Biosciences director Karen Jean Ferrante received a stock option award covering 686 shares of common stock. The options were granted on April 1, 2026 with an exercise price of $35.24 per share and expire on April 1, 2036.
The award was issued as compensation for her services as a non-employee director, where she elected to receive options instead of cash. After this grant, she directly holds options for 686 shares, providing equity-based compensation aligned with the company’s performance.
Fairmount Healthcare Fund II LP, an entity associated with Fairmount Funds Management LLC, converted 28,000 shares of Cogent Biosciences Series A Convertible Preferred Stock into 7,000,000 shares of Common Stock for no cash consideration on March 31, 2026. The fund then sold 7,000,000 Common shares in an open-market transaction at $34.66 per share, reducing its indirect Common Stock holdings to 5,503,418 shares. Following the conversion, it continues to hold 39,414 shares of Series A Convertible Preferred Stock, each convertible into 250 Common shares, subject to a 9.9% beneficial ownership cap.
Fairmount Funds Management LLC, as reporting person, disclosed that Fairmount Healthcare Fund II LP sold 3,500,000 shares of Cogent Biosciences, Inc. common stock on January 22, 2026 at a price of $36.40 per share. After this sale, Fund II held 5,503,418 shares of Cogent common stock indirectly reported by Fairmount Funds Management LLC.
The filing also shows that Fund II indirectly held 16,853,500 shares of Series A Convertible Preferred Stock, each share convertible at the holder’s option into 250 shares of common stock, subject to a 9.9% beneficial ownership cap. Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting and investment power over Fund II’s securities and disclaim beneficial ownership except to the extent of their pecuniary interest.